FimmCyte
Company

Last deal

$1.1M
Local Amount - CHF 1M

Amount

Convertible Note

Stage

28.02.2024

Date

7

all rounds

$3.5M

Total amount

General

About Company
FimmCyte is a biotechnology company that has developed the first disease modifying treatment for Endometriosis.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2022

Number of employees

Last funding type

Convertible Note

IPO status

Private

Description

FimmCyte's innovative immune system-based treatment has shown positive results in early preclinical studies. The company is dedicated to advancing women's health by developing treatments that address their unmet medical needs. By accelerating the path towards an endometriosis cure, FimmCyte aims to empower women to take control of their health. Through groundbreaking ideas and services, FimmCyte is committed to revolutionizing healthcare and improving the lives of women.
Contacts

Social url